Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by barcodewhizon Nov 13, 2009 3:11pm
236 Views
Post# 16485203

RE: RE: SABTO

RE: RE: SABTO

   I completely agree Sah.  The likely scenarios are,  partial adoption or full adoption.... both subject to DoH implementation timing.  I do like the fact that the SABTO committee itself has been touted as being influential.  I also like the fact that there has been a substantial amount of public pressure in the UK on this issue...   Makes it much tougher for DoH to duck the issue.  I frankly expect them to be proactive even despite budget pressures.  Its a miniscule rounding error in the overall scheme of things,  yet it puts public pressure to rest....  and dont forget it frees up the potential for the UK to reduce reliance on Blood imports, and turn back to their own supply.     Even a partial adoption is still great news for PLI.   You have to believe it would be focussed AT LEAST on high risk, pediatrics, and the whole blood collection system.

Regardless,  a positive recommendation gives latitude to other countries and furthers the whole process.
Bullboard Posts